Targeting the PD-1/PD-L1 axis—The first clinical application of anti-PD-1 in cancer has represented a true breakthrough [192] and, since then, the PD-1/PD-L1 axis blockade has become an approved therapeutic strategy in several cancer types, representing an unprecedented advancement in cancer treatment, as single agents or in combination with other anticancer agents [193]. This evidence concerns the gene CD274 and cancer.